Bristol Myers Squibb (CELG-RI) Profit After Tax Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Profit After Tax Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
11.09% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-183.48% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-8.70% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
8.77% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
8.77% |
| Date | Value |
|---|
| Mar 31, 2026 |
8.77% |
| Dec 31, 2025 |
1,677.05% |
| Sep 30, 2025 |
81.15% |
| Jun 30, 2025 |
-99.88% |
| Mar 31, 2025 |
120.67% |
| Dec 31, 2024 |
-96.54% |
| Sep 30, 2024 |
-37.18% |
| Jun 30, 2024 |
41,900.00% |
| Mar 31, 2024 |
-238,320.00% |
| Dec 31, 2023 |
-13.63% |
| Sep 30, 2023 |
20.27% |
| Jun 30, 2023 |
-99.72% |
| Mar 31, 2023 |
0.00% |
| Dec 31, 2022 |
-14.72% |
| Sep 30, 2022 |
4.01% |
| Jun 30, 2022 |
34.69% |
| Mar 31, 2022 |
-99.75% |
| Dec 31, 2021 |
123.86% |
| Sep 30, 2021 |
-17.68% |
| Jun 30, 2021 |
1,341.18% |
